27 March 2017

Oxford BioMedica Announces Publication in the Journal Nature Communications on Study Results Supporting the Transgene Repression in vector Production (TRiP) system


Data demonstrates benefits of the Group’s proprietary “TRiP” system in enhancing production yields for a broad range of gene therapy vectors

Oxford, UK – 27 March 2017: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces the publication of study results in the journal Nature Communications supporting the Group’s Transgene Repression in vector Production (TRiP) system.

This new vector production approach addresses a common problem of reduced yield during the manufacture of gene therapy vectors when the therapeutic gene is expressed highly in production cells. The TRiP system suppresses this undesirable expression without compromising expression of the therapeutic protein in target cells. The findings published in the peer-reviewed article demonstrate significant gains in the production yields of a broad range of gene therapy vectors, including those based on lentivirus, adenovirus and AAV. We believe that the improved yield facilitated by the TRiP system will allow significant reduction in production cost of the viral vector needed for a patient dose and also unlock the development for gene therapies that are currently made impractical due to this common problem.  

The publication in Nature Communications is entitled: “Enhancing titres of therapeutic viral vectors using the Transgene Repression in Vector Production (TRiP) system” DOI: 10.1038/NCOMMS14834.

The TRiP system is subject to patent applications derived from WO 2015/092440, which will expire in December 2034.

Commenting on the publication, John Dawson, Chief Executive Officer of Oxford BioMedica, said:

“The data published demonstrates Oxford BioMedica’s innovative capabilities and our commitment to invest in our technology to maintain our leading position in vector manufacture for gene therapy products. As demand for vectors grows with the introduction of gene and cell therapy products, we are confident there will be significant demand from third parties to licence the rights to utilise our TRiP technology.”

John Dawson

Chief Executive Officer of Oxford BioMedica

For further information, please contact:

Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000

Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700

Jefferies (Corporate Broker):
Gil Bar-Nahum
Simon Hardy
Lee Morton
Max Jones
Nicholas Moore
Tel: +44 (0)20 7029 8000

Jefferies (Corporate Broker):
Gil Bar-Nahum
Simon Hardy
Lee Morton
Max Jones
Nicholas Moore
Tel: +44 (0)20 7029 8000

Notes to editors
About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases.  Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products.  Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.


Back to previous page